English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Rhipicephalus sanguineus , the common brown dog tick, produces several chemokine‐binding proteins which are secreted into the host in its saliva to modulate the host response during feeding. Two of these demonstrate very restricted selectivity profiles. Here, we describe the characterization of the third, which we named Evasin‐4. Evasin‐4 was difficult to produce recombinantly using its native signal peptide in  HEK  cells, but expressed very well using the urokinase‐type plasminogen activator signal peptide. Using  SPR , Evasin‐4 was shown to bind most  CC  chemokines. Investigation of the neutralization properties by inhibition of chemokine‐induced chemotaxis showed that binding and neutralization did not correlate in all cases. Two major anomalies were observed: no binding was observed to  CCL 2 and  CCL 13, yet Evasin‐4 was able to inhibit chemotaxis induced by these chemokines. Conversely, binding to  CCL 25 was observed, but Evasin‐4 did not inhibit  CCL 25‐induced chemotaxis. Size‐exclusion chromatography confirmed that Evasin‐4 forms a complex with  CCL 2 and  CCL 18. In accordance with the standard properties of unmodified small proteins, Evasin‐4 was rapidly cleared following  in vivo  administration. To enhance the  in vivo  half‐life and optimize its potential as a therapeutic agent, Fc fusions of Evasin‐4 were created. Both the N‐ and C‐terminal fusions were shown to retain binding activity, with the C‐terminal fusion showing a modest reduction in potency.

Evasin‐4, a tick‐derived chemokine‐binding protein with broad selectivity can be modified for use in preclinical disease models